We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EXPD:NYSEExpeditors International of Washington, Inc. Analysis

Data as of 2026-03-10 - not real-time

$141.37

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Expeditors delivered a modest earnings beat this quarter, posting EPS of $1.49 versus the Zacks consensus of $1.46 (+2.06%), but revenue slipped 11.3% year‑over‑year. The company also announced a new share‑repurchase program, which adds a modest catalyst to the price action. At a market price of $141.37, the stock sits well above the DCF‑derived fair value of $88.75 and shows a negative upside/downside metric of -1.5%, suggesting limited near‑term upside. Technical gauges are mixed: the 20‑day and 50‑day SMAs (≈$147.8 and $154.6) sit above the current price, the RSI is at 38 indicating near‑oversold conditions, and the MACD remains bearish, while volume trends are decreasing and overall volatility is high at 54% over the past 30 days.
Fundamentally, EXPD boasts a strong ROE of 35% and a solid cash position that comfortably exceeds its debt load, supporting a sustainable dividend yield of 1.06% with a low payout ratio of 26%. The forward PE of ~22 is below the industry average of 29.4, though the price‑to‑book ratio of 8 is elevated. Beta is modest at 0.81, implying lower market sensitivity, and analysts collectively rate the stock as a “hold” with a median target of $140.5, essentially flat to the current price.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Earnings beat but revenue contraction
  • Bearish technical indicators (price below SMA20/50, MACD)
  • High short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong ROE and cash generation
  • Sustainable dividend with low payout ratio
  • Share repurchase program supporting price

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Durable logistics business model with global footprint
  • Low debt relative to cash and solid balance sheet
  • Attractive valuation relative to industry PE

Key Metrics & Analysis

Financial Health

Revenue Growth-3.30%
Profit Margin7.32%
P/E Ratio23.8
ROE35.43%
ROA13.64%
Debt/Equity24.20
P/B Ratio8.0
Op. Cash Flow$1.0B
Free Cash Flow$803.0M
Industry P/E29.4

Technical Analysis

TrendNeutral
RSI38.1
Support$129.59
Resistance$164.66
MA 20$147.76
MA 50$154.59
MA 200$131.97
MACDBearish
VolumeDecreasing
Fear & Greed Index76.91

Valuation

Fair Value$88.75
Target Price$139.29
Upside/Downside-1.47%
GradeOvervalued
TypeValue
Dividend Yield1.06%

Risk Assessment

Beta0.81
Volatility54.14%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.